Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | NA |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | anaplastic thyroid cancer |
| ICD-0-3 | C73 |
| Methods | qPCR |
| Sample | The human ATC lines 8505C, SW1736, KAT18, and Cal-62, Nthyori3-1 primary human thyroid follicular epithelial cells, 19 frozen ATC tissue and 19 patients with benign thyroid nodes who underwent thyroidectomy and/or or fine needle aspiration (FNA) tissues |
| Expression Pattern | up-regulated |
| Function Description | H19 was overexpressed in ATC tissues. Targeting H19 inhibited proliferation, migration, and invasion and induced apoptosis in 8505C cells in vitro and inhibited tumorigenesis and metastasis in vivo. Therefore, the H19 might be an effective target for ATC molecular therapy. |
| Pubmed ID | 31299871 |
| Year | 2019 |
| Title | Targeted inhibition of long non-coding RNA H19 blocks anaplastic thyroid carcinoma growth and metastasis |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for anaplastic thyroid cancer | OMIM COSMIC |